How do tenascins influence the birth and life of a malignant cell?

Journal of Cellular and Molecular Medicine

Volumn 16, Issue 1, 2012, Pages 32-40

  Brellier, Florence ^a   Chiquet Ehrismann, Ruth ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Angiogenesis; Cancer therapy; EMT; Extracellular matrix; Genomic instability; Mechanical forces; Metastasis; Microenvironment; Primary tumour; Stem cells; Stroma; Tenascin

Indexed keywords

ISOPROTEIN; TENASCIN;

ARTICLE; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; METABOLISM; METASTASIS; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; STEM CELL NICHE;

CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN ISOFORMS; SIGNAL TRANSDUCTION; STEM CELL NICHE; TENASCIN;

EID: 84855181728     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01360.x     Document Type: Article

References (97)

1. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011; 223: 162-76.
2. Milas L, Hirata H, Hunter N, et al Effect of radiation-induced injury of tumour bed stroma on metastatic spread of murine sarcomas and carcinomas. Cancer Res. 1988; 48: 2116-20.
3. Olumi AF, Grossfeld GD, Hayward SW, et al Carcinoma-associated fibroblasts direct tumour progression of initiated human prostatic epithelium. Cancer Res. 1999; 59: 5002-11.
4. Shekhar MP, Werdell J, Santner SJ, et al Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumour development and progression. Cancer Res. 2001; 61: 1320-6.
5. Chiquet-Ehrismann R. Tenascins. Int J Biochem Cell Biol. 2004; 36: 986-90.
6. Bourdon MA, Wikstrand CJ, Furthmayr H, et al Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. 1983; 43: 2796-805.
7. Chiquet-Ehrismann R, Mackie EJ, Pearson CA, et al Tenascin: an extracellular matrix protein involved in tissue interactions during foetal development and oncogenesis. Cell. 1986; 47: 131-9.
8. Scherberich A, Tucker RP, Samandari E, et al Murine tenascin-W: a novel mammalian tenascin expressed in kidney and at sites of bone and smooth muscle development. J Cell Sci. 2004; 117: 571-81.
9. Orend G. Potential oncogenic action of tenascin-C in tumourigenesis. Int J Biochem Cell Biol. 2005; 37: 1066-83.
10. Brellier F, Tucker RP, Chiquet-Ehrismann R. Tenascins and their implications in diseases and tissue mechanics. Scand J Med Sci Sports. 2009; 19: 511-9.
11. Jones PL, Jones FS. Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol. 2000; 19: 581-96.
12. Degen M, Brellier F, Kain R, et al Tenascin-W is a novel marker for activated tumour stroma in low-grade human breast cancer and influences cell behavior. Cancer Res. 2007; 67: 9169-79.
13. Degen M, Brellier F, Schenk S, et al Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer. 2008; 122: 2454-61.
14. Martina E, Degen M, Ruegg C, et al Tenascin-W is a specific marker of glioma-associated blood vessels and stimulates angiogenesisin vitro. Faseb J. 2010; 24: 778-87.
15. Tucker RP, Chiquet-Ehrismann R. The regulation of tenascin expression by tissue microenvironments. Biochim Biophys Acta. 2009; 1793: 888-92.
16. Tlsty TD. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol. 1998; 10: 647-53.
17. Chiquet-Ehrismann R, Tucker R. Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol. 2011; 3: a004960.
18. Ruiz C, Huang W, Hegi ME, et al Growth promoting signaling by tenascin-C [corrected]. Cancer Res. 2004; 64: 7377-85.
19. Thomasset N, Lochter A, Sympson CJ, et al Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol. 1998; 153: 457-67.
20. Valin A, Barnay-Verdier S, Robert T, et al PTCH1 +/- dermal fibroblasts isolated from healthy skin of Gorlin syndrome patients exhibit features of carcinoma associated fibroblasts. PLOS One. 2009; 4: e4818.
21. Reya T, Morrison SJ, Clarke MF, et al Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-11.
22. von Holst A. Tenascin C in stem cell niches: redundant, permissive or instructive? Cells Tissues Organs. 2008; 188: 170-7.
23. Garcion E, Halilagic A, Faissner A, et al Generation of an environmental niche for neural stem cell development by the extracellular matrix molecule tenascin C. Development. 2004; 131: 3423-32.
24. Yagi H, Yanagisawa M, Suzuki Y, et al HNK-1 epitope-carrying Tenascin-C spliced variant regulates the proliferation of mouse embryonic neural stem cells. J Biol Chem. 2010; 285: 37293-301.
25. He J, Liu Y, Xie X, et al Identification of cell surface glycoprotein markers for glioblastoma-derived stem-like cells using a lectin microarray and LC-MS/MS approach. J Proteome Res. 2010; 9: 2565-72.
26. Klein G, Beck S, Muller CA. Tenascin is a cytoadhesive extracellular matrix component of the human hematopoietic microenvironment. J Cell Biol. 1993; 123: 1027-35.
27. Ohta M, Sakai T, Saga Y, et al Suppression of hematopoietic activity in tenascin-C-deficient mice. Blood. 1998; 91: 4074-83.
28. Kloepper JE, Tiede S, Brinckmann J, et al Immunophenotyping of the human bulge region: the quest to define useful in situ markers for human epithelial hair follicle stem cells and their niche. Exp Dermatol. 2008; 17: 592-609.
29. Chiquet-Ehrismann R, Kalla P, Pearson CA. Participation of tenascin and transforming growth factor-beta in reciprocal epithelial-mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Res. 1989; 49: 4322-5.
30. Jotzu C, Alt E, Welte G, et al Adipose tissue-derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumour-derived factors. Anal Cell Pathol (Amst). 2010; 33: 61-79.
31. Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron. 2008; 1: 93-102.
32. Hirata E, Arakawa Y, Shirahata M, et al Endogenous tenascin-C enhances glioblastoma invasion with reactive change of surrounding brain tissue. Cancer Sci. 2009; 100: 1451-9.
33. Tucker RP, McKay SE. The expression of tenascin by neural crest cells and glia. Development. 1991; 112: 1031-9.
34. Tucker RP. Abnormal neural crest cell migration after thein vivoknockdown of tenascin-C expression with morpholino antisense oligonucleotides. Dev Dyn. 2001; 222: 115-9.
35. Huang W, Chiquet-Ehrismann R, Moyano JV, et al Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumour cell proliferation. Cancer Res. 2001; 61: 8586-94.
36. Taraseviciute A, Vincent BT, Schedin P, et al Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol. 2010; 176: 827-38.
37. Fukunaga-Kalabis M, Martinez G, Nguyen TK, et al Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population. Oncogene. 2010; 29: 6115-24.
38. Jahkola T, Toivonen T, Virtanen I, et al Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998; 78: 1507-13.
39. Chiquet-Ehrismann R, Kalla P, Pearson CA, et al Tenascin interferes with fibronectin action. Cell. 1988; 53: 383-90.
40. Wenk MB, Midwood KS, Schwarzbauer JE. Tenascin-C suppresses Rho activation. J Cell Biol. 2000; 150: 913-20.
41. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest. 2001; 107: 785-90.
42. Palecek SP, Loftus JC, Ginsberg MH, et al Integrin-ligand binding properties govern cell migration speed through cell-substratum adhesiveness. Nature. 1997; 385: 537-40.
43. Deryugina EI, Bourdon MA. Tenascin mediates human glioma cell migration and modulates cell migration on fibronectin. J Cell Sci. 1996; 109: 643-52.
44. Nishio T, Kawaguchi S, Yamamoto M, et al Tenascin-C regulates proliferation and migration of cultured astrocytes in a scratch wound assay. Neuroscience. 2005; 132: 87-102.
45. De Wever O, Nguyen QD, Van Hoorde L, et al Tenascin-C and SF/HGF produced by myofibroblastsin vitroprovide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. Faseb J. 2004; 18: 1016-8.
46. Murphy-Ullrich JE, Lightner VA, Aukhil I, et al Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol. 1991; 115: 1127-36.
47. Hancox RA, Allen MD, Holliday DL, et al Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res. 2009; 11: R24.
48. Scherberich A, Tucker RP, Degen M, et al Tenascin-W is found in malignant mammary tumours, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expressionin vitro. Oncogene. 2005; 24: 1525-32.
49. Maschler S, Grunert S, Danielopol A, et al Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumour cells. Oncogene. 2004; 23: 3622-33.
50. Dandachi N, Hauser-Kronberger C, More E, et al Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. J Pathol. 2001; 193: 181-9.
51. Tanaka S, Sumioka T, Fujita N, et al Suppression of injury-induced epithelial-mesenchymal transition in a mouse lens epithelium lacking tenascin-C. Mol Vis. 2010; 16: 1194-205.
52. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci. 1995; 108: 797-809.
53. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell. 1996; 7: 883-92.
54. Ballard VL, Sharma A, Duignan I, et al Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. Faseb J. 2006; 20: 717-9.
55. Tanaka K, Hiraiawa N, Hashimoto H, et al Tenascin-C regulates angiogenesis in tumour through the regulation of vascular endothelial growth factor expression. Int J Cancer. 2004; 108: 31-40.
56. Clasper S, Royston D, Baban D, et al A novel gene expression profile in lymphatics associated with tumour growth and nodal metastasis. Cancer Res. 2008; 68: 7293-303.
57. Cueni LN, Hegyi I, Shin JW, et al Tumour lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol. 2010; 177: 1004-16.
58. Schenk S, Muser J, Vollmer G, et al Tenascin-C in serum: a questionable tumour marker. Int J Cancer. 1995; 61: 443-9.
59. Martina E, Chiquet-Ehrismann R, Brellier F. Tenascin-W: an extracellular matrix protein associated with osteogenesis and cancer. Int J Biochem Cell Biol. 2010; 42: 1412-5.
60. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol. 2009; 41: 1452-62.
61. Calvo A, Catena R, Noble MS, et al Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumour growth and lung metastasis. Oncogene. 2008; 27: 5373-84.
62. Tavazoie SF, Alarcon C, Oskarsson T, et al Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008; 451: 147-52.
63. Pazzaglia L, Conti A, Chiechi A, et al Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases. Histopathology. 2010; 57: 59-72.
64. Chen J, Chen Z, Chen M, et al Role of fibrillar Tenascin-C in metastatic pancreatic cancer. Int J Oncol. 2009; 34: 1029-36.
65. Qiu TH, Chandramouli GV, Hunter KW, et al Global expression profiling identifies signatures of tumour virulence in MMTV-PyMT-transgenic mice: correlation to human disease. Cancer Res. 2004; 64: 5973-81.
66. Crisp M, Liu Q, Roux K, et al Coupling of the nucleus and cytoplasm: role of the LINC complex. J Cell Biol. 2006; 172: 41-53.
67. Ramos DM, Chen BL, Boylen K, et al Stromal fibroblasts influence oral squamous-cell carcinoma cell interactions with tenascin-C. Int J Cancer. 1997; 72: 369-76.
68. Sriramarao P, Mendler M, Bourdon MA. Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. J Cell Sci. 1993; 105: 1001-12.
69. Yokosaki Y, Palmer EL, Prieto AL, et al The integrin alpha 9 beta 1 mediates cell attachment to a non-RGD site in the third fibronectin type III repeat of tenascin. J Biol Chem. 1994; 269: 26691-6.
70. Varnum-Finney B, Venstrom K, Muller U, et al The integrin receptor alpha 8 beta 1 mediates interactions of embryonic chick motor and sensory neurons with tenascin-C. Neuron. 1995; 14: 1213-22.
71. Yokosaki Y, Monis H, Chen J, et al Differential effects of the integrins alpha9beta1, alphavbeta3, and alphavbeta6 on cell proliferative responses to tenascin. Roles of the beta subunit extracellular and cytoplasmic domains. J Biol Chem. 1996; 271: 24144-50.
72. Swindle CS, Tran KT, Johnson TD, et al Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for EGF receptor. J Cell Biol. 2001; 154: 459-68.
73. Iyer AK, Tran KT, Griffith L, et al Cell surface restriction of EGFR by a tenascin cytotactin-encoded EGF-like repeat is preferential for motility-related signaling. J Cell Physiol. 2008; 214: 504-12.
74. Midwood K, Sacre S, Piccinini AM, et al Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med. 2009; 15: 774-80.
75. Martin D, Brown-Luedi M, Chiquet-Ehrismann R. Tenascin-C signaling through induction of 14-3-3 tau. J Cell Biol. 2003; 160: 171-5.
76. Wang B, Liu K, Lin HY, et al 14-3-3 Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer. Mol Cell Biol. 2010; 30: 1508-27.
77. Brosig M, Ferralli J, Gelman L, et al Interfering with the connection between the nucleus and the cytoskeleton affects nuclear rotation, mechanotransduction and myogenesis. Int J Biochem Cell Biol. 2010; 42: 1717-28.
78. Chung CY, Zardi L, Erickson HP. Binding of tenascin-C to soluble fibronectin and matrix fibrils. J Biol Chem. 1995; 270: 29012-7.
79. Chung CY, Erickson HP. Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J Cell Sci. 1997; 110: 1413-9.
80. Day JM, Olin AI, Murdoch AD, et al Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem. 2004; 279: 12511-8.
81. Fischer D, Chiquet-Ehrismann R, Bernasconi C, et al A single heparin binding region within the fibrinogen-like domain is functional in chick tenascin-C. J Biol Chem. 1995; 270: 3378-84.
82. Zacharias U, Norenberg U, Rathjen FG. Functional interactions of the immunoglobulin superfamily member F11 are differentially regulated by the extracellular matrix proteins tenascin-R and tenascin-C. J Biol Chem. 1999; 274: 24357-65.
83. Czopka T, von Holst A, ffrench-Constant C, et al Regulatory mechanisms that mediate tenascin C-dependent inhibition of oligodendrocyte precursor differentiation. J Neurosci. 2010; 30: 12310-22.
84. Brellier F, Ruggiero S, Zwolanek D, et al SMOC1 is a tenascin-C interacting protein overexpressed in brain tumours. Matrix Bio. 2011; 225-33.
85. Paszek MJ, Zahir N, Johnson KR, et al Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005; 8: 241-54.
86. Levental KR, Yu H, Kass L, et al Matrix crosslinking forces tumour progression by enhancing integrin signaling. Cell. 2009; 139: 891-906.
87. Yang R, Amir J, Liu H, et al Mechanical strain activates a program of genes functionally involved in paracrine signaling of angiogenesis. Physiol Genom. 2008; 36: 1-14.
88. Maier S, Lutz R, Gelman L, et al Tenascin-C induction by cyclic strain requires integrin-linked kinase. Biochim Biophys Acta. 2008; 1783: 1150-62.
89. Sarasa-Renedo A, Tunc-Civelek V, Chiquet M. Role of RhoA/ROCK-dependent actin contractility in the induction of tenascin-C by cyclic tensile strain. Exp Cell Res. 2006; 312: 1361-70.
90. Chiquet-Ehrismann R, Tannheimer M, Koch M, et al Tenascin-C expression by fibroblasts is elevated in stressed collagen gels. J Cell Biol. 1994; 127: 2093-101.
91. Blaauboer ME, Smit TH, Hanemaaijer R, et al Cyclic mechanical stretch reduces myofibroblast differentiation of primary lung fibroblasts. Biochem Biophys Res Commun. 2011; 404: 23-7.
92. Helleman J, Jansen MP, Ruigrok-Ritstier K, et al Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res. 2008; 14: 5555-64.
93. Gong XG, Lv YF, Li XQ, et al Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells. Biol Pharm Bull. 2010; 33: 1261-7.
94. Lal A, Peters H, St Croix B, et al Transcriptional response to hypoxia in human tumours. J Natl Cancer Inst. 2001; 93: 1337-43.
95. Caruso G, Caffo M, Raudino G, et al Antisense oligonucleotides as innovative therapeutic strategy in the treatment of high-grade gliomas. Recent Pat CNS Drug Discov. 2010; 5: 53-69.
96. Ireson CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006; 5: 2957-62.
97. Schliemann C, Neri D. Antibody-based vascular tumour targeting. Recent Results Cancer 2010; 180: 201-16.